



# <span id="page-0-0"></span>**Virulence and tissue tropism of different epidemiologically significant SARS-CoV-2 variants for golden Syrian hamsters**

Anastasiia V. Gracheva<sup>1¤</sup>, Andrey O. Drokov<sup>1</sup>, Daria I. Smirnova<sup>1</sup>, Darya M. Khokhlova<sup>1</sup>, Ekaterina R. Korchevaya<sup>1</sup>, Andrey A. Pankratov<sup>3</sup>, Galina V. Trunova<sup>3</sup>, Varvara A. Khokhlova<sup>3</sup>, Maria S. Vorontsova<sup>3</sup>, Irina A. Leneva<sup>1</sup>, Oxana A. Svitich<sup>1,2</sup>, Vitaly V. Zverev<sup>1,2</sup>, Evgeny B. Faizuloev<sup>1, 4</sup>

1 I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia;

2 I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;

3 P.A. Hertsen Moscow Oncology Research Institute — the branch of the National Medical Research Radiological Center, Moscow, Russia;

4 Russian Medical Academy of Continuous Professional Education, Moscow, Russia

#### *Abstract*

**Introduction.** Animal models for SARS-CoV-2 infection, reproducing the clinical features of COVID-19 in humans, are important tools for studying the pathogenesis of the disease, transmission of the pathogen and are indispensable for testing antiviral drugs and vaccines.

**The aim** of the study was to assess the virulence and tissue tropism for golden Syrian hamsters of SARS-CoV-2 strains belonging to different variants of concern: Wuhan-like, Delta, Omicron BA.1.1 and Omicron BA.5.2.

**Materials and methods.** Hamsters were intranasally infected with different SARS-CoV-2 strains. Virulence and tissue tropism of SARS-CoV-2 strains were assessed by comparing the dynamics of weight, viral load in organs and histopathological changes in lungs in infected and uninfected animals.

**Results.** The Wuhan-like Dubrovka strain had the greatest virulence for hamsters, which was manifested by the development of severe pneumonia and a delay in weight gain by 14.6%, high virus content in the lungs, nasal passages and brain  $-6.2$ , 5,9 and 3.7 log10 TCID<sub>50</sub>/ml of homogenate, respectively. Presumably, it was the infection of the Wuhan-like virus of the central nervous system that negatively affected the weight and general condition of the animals. When hamsters were infected with viruses belonging to the Delta and Omicron variants, the observed minor weight loss in animals was uninformative, so indicators such as lung histopathology, viral load in the lungs, nasal passages, heart and other organs played a decisive role in assessing the virus pathogenicity. A score assessment of lung histopathology was of particular value in assessing the severity of pneumonia, since it reduced subjectivity in evaluating the results of histological examination and provided a semi-quantitative assessment of the pathological process.

**Conclusion.** Despite the revealed lower virulence for hamsters of viruses belonging to the Delta and Omicron variants compared to the ancestral Wuhan virus, this animal model for COVID-19 retains its value for conducting preclinical trials of antiviral drugs.

**Keywords:** *animal model for COVID-19, golden Syrian hamsters, virulence, tissue tropism, epidemiologically significant SARS-CoV-2 variants*

*Ethics approval.* Authors confirm compliance with institutional and national standards for the use of laboratory animals in accordance with «Consensus Author Guidelines for Animal Use» (IAVES, 23 July 2010). The research protocol was approved by the Ethics Committee of the I.I. Mechnikov Research Institute for Vaccines and Sera (protocol No. 2, May 24, 2021).

*Funding source.* Исследование выполнено за счёт гранта Российского научного фонда № 23-25-00146, https://rscf.ru/project/23-25-00146/. В исследовании использовано научное оборудование центра коллективного пользования «НИИВС им. И.И. Мечникова» — при финансовой поддержке проекта Российской Федерацией в лице Минобнауки России.

*Conflict of interest.* The authors declare no apparent or potential conflicts of interest related to the publication of this article.

*For citation:* Gracheva A.V., Drokov A.O., Smirnova D.I., Khokhlova D.M., Korchevaya E.R., Pankratov A.A., Trunova G.V., Khokhlova V.A., Vorontsova M.S., Leneva I.A., Svitich O.A., Zverev V.V., Faizuloev E.B. Virulence and tissue tropism of different epidemiologically significant SARS-CoV-2 variants for golden Syrian hamsters. *Journal of microbiology, epidemiology and immunobiology.* 2024;101(4):470–482. DOI: https://doi.org/10.36233/0372-9311-528

EDN: https://www.elibrary.ru/jukmca

<sup>©</sup> Gracheva A.V., Drokov A.O., Smirnova D.I., Khokhlova D.M., Korchevaya E.R., Pankratov A.A., Trunova G.V., Khokhlova V.A., Vorontsova M.S., Leneva I.A., Svitich O.A., Zverev V.V., Faizuloev E.B., 2024

## **Вирулентность и тканевая специфичность разных эпидемически значимых вариантов SARS-CoV-2 для золотистых сирийских хомячков**

**Грачева А.В.1⊠, Дроков А.О.', Смирнова Д.И.', Хохлова Д.М.', Корчевая Е.Р.',** Панкратов А.А.<sup>з</sup>, Трунова Г.В.<sup>з</sup>, Хохлова В.А.<sup>з</sup>, Воронцова М.С.<sup>з</sup>, Ленева И.А.<sup>1</sup>, **Свитич О.А.1, 2, Зверев В.В.1, 2, Файзулоев Е.Б.1, 4**

1 Научно-исследовательский институт вакцин и сывороток имени И.И. Мечникова, Москва, Россия; 2 Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет), Москва, Россия;

 $^3$ Московский научно-исследовательский онкологический институт имени П.А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России, Москва, Россия;

4 Российская медицинская академия непрерывного профессионального образования, Москва, Россия

#### *Аннотация*

**Введение.** Животные модели инфекции SARS-CoV-2, воспроизводящие клинические особенности COVID-19 у человека, являются важными инструментами изучения патогенеза заболевания, трансмиссии возбудителя и незаменимы при испытаниях противовирусных лекарственных препаратов и вакцин.

**Целью** исследования являлась оценка вирулентности и тканевой специфичности для золотистых сирийских хомячков штаммов SARS-CoV-2, относящихся к разным эпидемически значимым вариантам: Ухань-подобному, Delta, Omicron BA.1.1 и Omicron BA.5.2.

**Материалы и методы.** Хомячков интраназально заражали разными штаммами SARS-CoV-2. Вирулентность и тканевую специфичность штаммов SARS-CoV-2 оценивали путём сравнения динамики массы, вирусной нагрузки в органах и выраженности патоморфологических изменений в лёгких у заражённых и незаражённых животных.

**Результаты.** Наибольшей вирулентностью для хомячков обладал Ухань-подобный штамм, что проявлялось в развитии тяжёлой пневмонии и задержке в приросте массы на 14,6%, высоком содержании вируса в лёгких, носовых ходах и головном мозге — 6,2, 5,9 и 3,7 lg ТЦД<sub>50</sub>/мл гомогената соответственно. Предположительно именно поражение Ухань-подобным вирусом центральной нервной системы негативно повлияло на показатели массы и общее состояние животных. При заражении хомячков штаммами, относящимися к вариантам Delta и Omicron, незначительная потеря массы животными была неинформативной, поэтому при оценке патогенности вируса решающую роль играли такие показатели, как гистопатология лёгких, вирусная нагрузка в лёгких, носовых ходах, сердце и других органах. Особую ценность при сравнении тяжести пневмонии имела балльная оценка выраженности патоморфологических изменений в лёгких, поскольку она снижала субъективизм в оценке результатов гистологического исследования и давала полуколичественную оценку патологического процесса.

**Заключение.** Несмотря на выявленную более низкую вирулентность для хомячков штаммов, относящихся к вариантам Delta и Omicron, по сравнению с родоначальным Уханьским вирусом, данная животная модель COVID-19 сохраняет свою ценность для проведения доклинических испытаний противовирусных препаратов.

**Ключевые слова:** *животная модель COVID-19, золотистые сирийские хомячки, вирулентность, тканевая специфичность, эпидемически значимые варианты SARS-CoV-2*

Этическое утверждение. Авторы подтверждают соблюдение институциональных и национальных стандартов по использованию лабораторных животных в соответствии с «Consensus Author Guidelines for Animal Use» (IAVES, 23.07.2010). Протокол исследования одобрен Этическим комитетом НИИВС им. И.И. Мечникова (протокол № 2 от 24.05.2021).

*Источник финансирования.* Исследование выполнено за счёт гранта Российского научного фонда № 23-25- 00146, https://rscf.ru/project/23-25-00146/. В исследовании использовано научное оборудование центра коллективного пользования «НИИВС им. И.И. Мечникова» — при финансовой поддержке проекта Российской Федерацией в лице Минобрнауки России.

*Конфликт интересов.* Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.

*Для цитирования:* Грачева А.В., Дроков А.О., Смирнова Д.И., Хохлова Д.М., Корчевая Е.Р., Панкратов А.А., Трунова Г.В., Хохлова В.А., Воронцова М.С., Ленева И.А., Свитич О.А., Зверев В.В., Файзулоев Е.Б. Вирулентность и тканевая специфичность разных эпидемически значимых вариантов SARS-CoV-2 для золотистых сирийских хомячков. *Журнал микробиологии, эпидемиологии и иммунобиологии.* 2024;101(4):470–482. DOI: https://doi.org/10.36233/0372-9311-528 EDN: https://www.elibrary.ru/jukmca

<sup>©</sup> Грачева А.В., Дроков А.О., Смирнова Д.И., Хохлова Д.М., Корчевая Е.Р., Панкратов А.А., Трунова Г.В., Хохлова В.А., Воронцова М.С., Ленева И.А., Свитич О.А., Зверев В.В., Файзулоев Е.Б., 2024

## **Introduction**

Modeling viral diseases in laboratory animals is one of the most important problems of medical virology. The emergence in 2019 and global spread of SARS-CoV-2 coronavirus (*Severe acute respiratory syndromerelated coronavirus* species, *Betacoronavirus* genus, *Coronaviridae* family), accompanied by a high rate of hospitalization and mortality among those who became ill, necessitated the urgent development of treatments and specific prophylaxis for COVID-19, which is impossible without preclinical testing in adequate animal models of the disease. Since the beginning of the pandemic, considerable efforts have been made to develop effective and safe vaccines and therapeutic agents, and studies of the pathogenesis and features of the immune response to SARS-CoV-2 infection have been conducted [1]. The success of these studies largely depended on the availability of animal models for coronavirus infection developed in the first decade of the 2000s against the background of the threat of worldwide spread of SARS-CoV-1, the causative agent of severe acute respiratory syndrome [2], which belongs to the same species as SARS-CoV-2. Animal models for infection that reproduce clinical and pathological features of COVID-19 in humans are important tools for studying the pathogenesis of the disease, pathogen transmission and are indispensable for testing new antiviral drugs and vaccines [3–5].

To date, there are several animal models for COVID-19, primarily based on representatives of primate, carnivore and rodent groups. However, the problem of selecting the most adequate, informative and convenient model remains relevant. The value of primate-based animal models for coronavirus pneumonia lies in the fact that monkeys are similar to humans in their physiological characteristics and immune regulation. Rhesus macaques, African green monkeys, baboons, and common marmosets are most often used for COVID-19 modeling [1, 6, 7]. The main drawbacks of such models are the huge demand for animals, high cost, shortage of trained personnel and primate vivariums equipped according to biosafety level 3 requirements [1, 6].

Mink, ferrets and cats are also susceptible to SARS-CoV-like coronaviruses [7-11]. Notably, SARS-CoV-2 is found in the nasal cavity of ferrets and they can be infected by indirect contact, indicating the ability of ferrets and mink to transmit the virus by mimicking the SARS-CoV-2 transmission pathway in humans. A disadvantage of such models is that these animals are relatively large carnivores, so handling them is difficult. Therefore, there is a need for models based on small laboratory animals that are susceptible to the virus.

Mice and other rodents are most commonly used to model COVID-19. However, wild-type mice are not susceptible to infection with the ancestral Wuhan-like virus SARS-CoV-2 [5, 6, 12] because the virus is able to bind efficiently to the human ACE2 receptor (hACE2) but not to murine ACE2 (mACE2). Our previous findings indicate that Wuhan-like virus does not cause productive infection in BALB/c mice and, in contrast, when infected with Omicron-like virus multiplies in lungs, brain tissue, and other organs [5].

Several lines of genetically modified mice with hACE2 receptor are known, which have been adapted for studies on the pathogenesis of cardiovascular diseases and modeling of coronavirus infection [6, 12]. These transgenic mouse lines, with different origin, are capable of stable hACE2 expression in many organs. The mouse model also has some serious limitations, including differences in hACE2 expression patterns in different organs and tissues in humans and mice. Because hACE2 expression in transgenic mice is not physiologic, infection with SARS-CoV-2 can cause clinical manifestations and pathologic changes uncharacteristic of humans [1]. In addition, transgenic mice are not widely available in Russia and are characterized by high cost.

Among SARS-CoV-2 susceptible animals, the golden Syrian hamster (*Mesocricetus auratus*; hereafter hamsters) is of particular interest. Genetic comparison of hACE2 with analogous receptors of other mammals showed that the amino acid sequence of hamster ACE2 is very similar to that of the analogous human receptor, with which it has only 3-4 differences. In addition, hamster ACE2 has shown high affinity for the S-protein of SARS-CoV-2 and SARS-CoV in several studies [1, 3, 7].

The hamster model for coronavirus pneumonia is widely used in preclinical studies of vaccines and drugs [13]. Symptoms, disease pathogenesis and immune responses characteristic of COVID-19 in humans are well reproduced in hamsters [3, 14]. Hamsters are also in demand for modeling other human respiratory viral infections [14] caused by viruses such as SARS-CoV-1 [2], influenza viruses [15, 16] and adenoviruses [14, 17]. With advantages such as high reproduction rate, easy handling, affordable cost and availability in nurseries, hamsters are an optimal choice compared to other small laboratory animals.

Coronavirus disease caused in hamsters by Wuhan-like strains of SARS-CoV-2 has been well studied and characterized to date [13, 18-20]. Since at the current stage of the epidemic process, the ancestral SARS-CoV-2 virus has been replaced by new variants of concern (first Delta, then Omicron and its progeny), it is of interest to study their virulence and disease pathogenesis in infected hamsters. Previously, we conducted a study of the protective activity of a prototype live attenuated vaccine against SARS-CoV-2 in hamsters, which included their infection not only with the parental Wuhan-type virus, but also with strains belonging to Delta and Omicron variants [21]. In this article, we considered it appropriate to review and discuss the results obtained in more detail in the context of the pathogenicity of different virus variants for non-immunized hamsters.

**The aim** of the study was to assess the virulence and tissue specificity of SARS-CoV-2 strains belonging to different variants of concern in Syrian golden hamsters.

## **Materials and methods**

### *Virus*

Laboratory strains of SARS-CoV-2 isolated at the I.I. Mechnikov Research Institute of Virus Diseases from patients with confirmed diagnosis of COVID-19 during different periods of the pandemic were used in the study (**Table 1**). All works with SARS-CoV-2 virus were conducted in the conditions of the biosafety level 3 laboratory.

SARS-CoV-2 was cultured in Vero CCL81 (ATCC) kidney epithelial cell culture of African green monkey (hereinafter referred to as Vero) at 37<sup>o</sup>C in DMEM medium based on Earle's buffer (PanEco) with 5% fetal bovine serum (Gibco), 300 μg/mL L-glutamine (PanEco), 40 μg/mL gentamicin (PanEco) in an atmosphere of  $5\%$  CO<sub>2</sub>. A three-day-old monolayer of Vero cells was infected with SARS-CoV-2 virus at a multiplicity of infection  $MOI = 0.001$ . Virus adsorption was performed in a  $CO<sub>2</sub>$  incubator for 60 min, then maintenance medium (DMEM, 300 μg/mL L-glutamine, 40 μg/mL gentamicin) was added and incubated at 37⁰C until the appearance of pronounced cytopathic action (CPA) in an atmosphere of 5%  $CO<sub>2</sub>$ . After the appearance of pronounced CPA, the culture fluid was clarified by centrifugation at 4000 rpm for 10 min and stored at -80<sup>o</sup>C until used in experiments.

The titer of SARS-CoV-2 was determined in Vero cell culture by CPA endpoint. Tenfold dilutions of virus in 4 repeats were added to the wells of a 96-well plate with a 3-day-old monolayer of Vero cells and incubated for 5 days at 37 °C in an atmosphere of 5%  $CO_2$ . Titration results were evaluated by microscopic examination of the cell monolayer for the presence of characteristic CPA (rounding of cells and detachment of cells from the monolayer). Virus titer was calculated as described by M.A. Ramakrishnan et al. [22], and expressed in  $log10$  TCID<sub>50</sub>/mL.

#### *Animal models*

4-week-old female SPF hamsters (*n* = 30) weighing 40-45 g (SPP Nursery for Laboratory Animals, Branch of the Institute of Bioorganic Chemistry of the RAS, Russia) were used in this work. Hamsters were randomly distributed into groups. The animals were kept in accordance with the rules for the arrangement, equipment and maintenance of experimental and biological clinics. The animals were fed with briquetted feed according to the approved norms. The authors complied with institutional and national standards for the use of laboratory animals in conducting the experimental animal study. The conduct of the study was approved by the Ethical Committee of the I.I. Mechnikov Research Institute of Veterinary Medicine (protocol No. 2 of 24.05.2021).

#### *Study design*

The study design is schematically presented in **Fig. 1**. Hamsters were divided into 5 groups of 6 animals each and intranasally infected with different virus strains (Table 1) at a dose of  $10^4$  TCID<sub>50</sub>/head (100 μl each). For intranasal infection, animals were anesthetized and held in an upright position. The negative control group received an equivalent volume of phosphate-salt buffer pH 7.2. Weight control was performed daily. Four days after infection, the animals were humanely euthanized. The right hamster lung was fixed in 10% neutral buffered formalin for histologic examination. Tissues of lung, brain, nasal passages, heart, liver, spleen, kidney and blood were collected, homogenized in 1 ml DMEM medium with gentamicin (40 μg/ml, PanEco) using a Tissue Lyser LT homogenizer (Qiagen) and centrifuged at 10,000 rpm for 5 min at 4ºC. The supernatant was collected for measurement of virus titers and viral RNA concentration and stored at –80ºC until examination. Changes in body weight from day 1 to day 4 after infection, virus titer and viral RNA content in organs and tissues, and severity of inflammatory changes in the lungs of animals on day 4 after infection reflected the virulence of the strain, and the distribution of viral RNA and infectious virus in organs and tissues reflected its tissue specificity.

#### *SARS-CoV-2 RNA quantification*

The accumulation of viral RNA in organs and tissues was assessed by quantitative reverse transcription polymerase chain reaction as described previously [23]. Viral RNA was isolated from samples using the MagnoPrime UNI reagent kit (NextBio). To detect viral RNA, primers and probe designed for the SARS-CoV-2 nucleocapsid (N) gene were used, as proposed by J. Chan et al. [24].

**Table 1.** Characteristics of SARS-CoV-2 strains used in the study

Strain	Collection date	GenBank ID	Variant	Pangolin lineage	Passage level	Titer, $log 10$ TCID <sub>so</sub> /ml
Dubrovka	04.06.2020	MW514307.1	Wuhan-like	B.1.1.317	17	7,85
Podolsk	10.08.2021	ON032860.1	Delta	AY 122	16	7,0
Otradnoe	25.01.2022	ON032857.1	Omicron	<b>BA.1.1</b>		6,0
FEB <sub>2</sub>	11.10.2022	OP920753.1	Omicron	<b>BA.5.2</b>	4	6,5

[ORIGINAL RESEARCHES](#page-0-0)



**Fig. 1.** Study design. The infection dose of 4.0 log10 TCID $_{50}$  per animal.

## *Histologic examination of the lungs*

The right hamster lung was fixed in 10% neutral buffered formalin (BioVitrum) for 24 h, dehydrated according to the standard histological technique and placed in Histomix paraffin medium (BioVitrum). On the Leica RM 2125 RTS rotary microtome we made stepwise longitudinal sections 3-5 microns thick, the preparations were stained with hematoxylin and eosin, enclosed in Canadian balsam (Sigma-Aldrich). Histological preparations were examined using a BX51 light microscope (Olympus). Photofixation of the obtained lung histologic preparations was performed with the help of an Olympus XC10 camera. Pathomorphologic changes in the lungs were evaluated by 2 specialists using a blind method, using a combined severity score from 0 to 3 for each of the morphologic criteria proposed by A.D. Gruber et al. [25]. The maximum possible score was 60.

## *Statistical processing of data*

Statistical analysis was performed using the Graphpad Prism v. 8.0.01 software. Data are presented in graphs as mean, standard deviation (SD), standard error (SE), median, upper and lower quartiles. In box plots, the boundaries of the box are the upper and lower quartiles of the sample (25% and 75%), the ends of the whiskers are the boundaries of a statistically significant sample (without outliers), the line in the box itself is the median of the data. Statistical processing of the obtained results was carried out using the nonparametric method (Mann-Whitney U-test). Differences were considered statistically significant at  $p < 0.05$ .

## **Results**

Morphologic changes were absent in histologic preparations of the right lung of uninfected animals (**Fig. 2**).

On the 4th day after infection, broncho-interstitial pneumonia was detected in histologic preparations of hamster lungs of all groups (**Fig. 2**). However, there were significant differences in the severity and prevalence of alterative-inflammatory changes between the groups.

On the  $4<sup>th</sup>$  day after infection, the groups of animals infected with Wuhan-like Dubrovka strain and FEB2 strain (BA 5.2) showed similar in nature and severity inflammatory changes, the morphological picture of which corresponded to bronchointerstitial pneumonia in the viral stage. The lumen of bronchi and bronchioles in the foci of pneumonia often contained cellular debris, macrophages and neutrophils. The integrity of epithelial lining was focally disturbed due to migration of lymphoid cells, dystrophy, necrosis and desquamation of epitheliocytes. There were loci of epithelial hyperplasia. The wall of bronchi and bronchioles was moderately infiltrated with lymphocytes, histiocytes with a small admixture of polymorphonuclear lymphocytes. Dilated lymphatic vessels located along the course of the bronchial tree contained clusters of lymphocytes. Large lymphoid accumulations (hyperplasia of bronchoassociated lymphoid tissue) were found in the bronchial bifurcation zones. Inflammatory changes were also observed in the walls of medium and small branches of the pulmonary artery accompanying the airways. Perivascular lymphoid tissue was in a state of sharp hyperplasia.

Large confluent foci of pneumonia were observed in all lobes of the organ and were located along the course of the bronchial tree, spreading to the periphery. Their area, estimated at qualitative level, occupied 50- 90% of the histologic section area of the organ. Respiratory department in the pneumonia foci represented airless fields, lumen of alveoli in which were not defined, interalveolar septa were destroyed due to expressed lymphoid-histiocytic infiltrate with insignificant admixture of neutrophils. Remains of dead cells nuclei, fibroblasts, erythrocytes were seen among the cells of inflammatory infiltrate. In fresher areas of pneumonia airiness of respiratory section was reduced due to sharp



Fig. 2. Bronchointerstitial pneumonia in hamster on the 4<sup>th</sup> day post-challenge with different SARS-CoV-2 strains.

thickening of interalveolar septa and expressed exudation into the alveolar cavity of liquid blood and cells of inflammatory infiltrate: macrophages, lymphocytes, erythrocytes. Many alveoli contained eosinophilic filamentous material (presumably fibrin). In the interalveolar septa there was microvascular hypertension, interstitial edema and diffusely scattered lymphoid-histiocytic infiltrate.

On the 4th day after infection with Podolsk (Delta) strain, the severity and prevalence of inflammatory changes in hamster lungs were lower compared to those in the groups of animals infected with Wuhan-like virus and FEB2 strain (BA.5.2). Small foci of interstitial pneumonia were not located in all lobes, were located along the course of large lobular and segmental bronchi, and their area did not exceed 50% of the histologic section area of the organ. The lumen of bronchi and bronchioles in the foci of pneumonia were mostly free, contained single macrophages, lymphocytes, small groups of desquamated epitheliocytes. The epithelial lining looked preserved over a large length, with single lymphocytes in the field of view of the ×20 objective lens among the cells of the mesenteric epithelium. Airiness of pulmonary parenchyma in the foci of pneumonia was reduced due to thickening of interalveolar septa. Small groups of macrophages, lymphocytes, single neutrophils, erythrocytes and few dead cells (presumably, alveolocytes) were observed in the alveolar cavity. Proteinaceous exudate in the lumen of the alveoli was rare. At this period of the experiment airless and confluent foci of pneumonia were practically absent.

In histologic preparations of hamster lungs euthanized on the  $4<sup>th</sup>$  day after infection with Otradnoe strain (BA.1.1), the least pronounced pathomorphological changes were observed compared to other groups. Small foci of interstitial pneumonia, which occupied no more than 5–7% of the total section area, were located in 2–3 lobes mainly in the root areas along the course of lobular bronchi. Inflammatory changes in the wall of bronchi and accompanying vessels were weakly expressed.

During histologic examination of the lungs of infected and uninfected hamsters, the morphologic manifestations of coronavirus pneumonia were graded using the recommendations of A.D. Gruber et al. [25]. In infected animals, the cumulative score reflecting the severity of the inflammatory process ranged from 20.8 to 49.8, while in uninfected animals it was close to zero (**Fig. 3**). In the group of animals infected with Wuhan-like virus, the mean value of the cumulative severity score was  $50 \pm 6$ , Delta —  $30 \pm 5$ , BA.1.1 —  $21 \pm 7$ , BA.5.2 — 39  $\pm$  6.

In addition to the severity of pathologic changes in hamster lungs, weight dynamics was an important criterion in assessing the virulence of different SARS-CoV-2 strains. The greatest difference in weight of infected and uninfected animals was observed on the 3rd or 4th day after infection. In the group of animals infected with Wuhan-like virus, the delay in weight gain was 14.6% compared to uninfected animals. The similar figure in animals infected with Delta, BA.1.1 and BA.5.2 averaged 2–3% (**Fig. 4**).

Since the main target organs for SARS-CoV-2 are the lungs, nasal passages and brain, not only the viral RNA content but also the infectious activity of the virus was investigated in these organs. The mean values of virus titer in tissues and organs of animals differed significantly depending on the strain used for infection. Thus, on the 4th day after infection, the highest titer values were observed in lung homogenates in groups of animals infected with Delta and Wuhan-like viruses on average 7.4 log10 and 6.2 log10 TCID<sub>50</sub>/mL of homogenate, whereas in groups infected with BA.1.1 and BA.5.2, the virus titer was significantly lower  $-4.6$ and 5.0 log10 TCID<sub>50</sub>/mL of homogenate, respectively (**Fig. 5**). In nasal passages homogenates, infectious virus was detected in animals of all groups at a titer of 4.9–6.8 log10 TCID<sub>50</sub>/mL of homogenate. In brain tissue, infectious virus was detected only in animals infected with Wuhan-like virus (on average 3.7 log10  $TCID_{50}/mL$  of homogenate). It should be noted that the tissue homogenates were toxic to the Vero cells in which the titration was performed; therefore, the limit of sensitivity was 2.0 log10 TCID<sub>50</sub>/mL of homogenate.



**Fig. 3.** Histopathology score of hamster lungs on day 4 post-infection with different SARS-CoV-2 strains. \**р* < 0.05; \*\**р* < 0.01.

In the lungs of infected animals, the concentration of viral RNA varied depending on the strain from 7.6 to 9.3 on average, in the nasal passages from 8.3 to 9.3, and in the brain from 3.8 to 7.6 log10 RNA copies/mL of homogenate (**Fig. 6**). The highest level of viral RNA in the lungs, nasal passages, brain and other organs of hamsters was observed in the groups of animals infected with Wuhan-like virus and Delta. The concentration of viral RNA in brain homogenates of animals infected with Wuhan-like virus was 7.6, Delta — 5.6, BA.1.1 and  $BA.5.2 - 3.8$  and 4.1 log10 RNA copies/mL, respectively.

Viral RNA was also detected in the heart, liver, kidney, spleen, and blood of most infected animals, but at much lower levels than in the lungs and nasal



**Fig. 4.** Weight dynamics in hamsters infected intranasally with different SARS-CoV-2 strains. K– — uninfected hamsters.

ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ



Fig. 5. Titer values of different SARS-CoV-2 strains in the organs of Syrian hamsters on the 4<sup>th</sup> day after infection. \**р* < 0.05; \*\**р* < 0.01.



**Fig. 6.** Distribution of viral RNA in the organs of hamsters infected with different SARS-CoV-2 strains. \**р* < 0.05; \*\**р* < 0.01.

passages (Fig. 6). The concentration of viral RNA in the above organs of animals infected with BA.1.1 and BA.5.2 was significantly ( $p < 0.05$ ) lower than in Wuhan-like virus and Delta infection (Fig. 6). The lowest viral RNA content in organs was observed in BA.5.2 infection, while no viral RNA was detected in the blood, kidney and spleen of most animals. It is noteworthy that in all groups of infected animals a significant content of viral RNA was observed in the heart — from 4.7 to 6.1 log10 RNA copies/mL of homogenate.

## **Discussion**

The design of the study implied equality of all conditions, including a single dose of  $10^4$  TCID<sub>50</sub>/head, except that different virus strains were administered to animals of different groups. Since SARS-CoV-2 is a re-

spiratory virus and is transmitted by airborne droplets, the correctness of our choice of intranasal route of virus administration in COVID-19 modeling is undoubted. This method of administration mimics the natural route of infection and is the simplest, fastest and non-invasive way to infect small laboratory animals such as mice and hamsters [4].

Our study revealed differences in virulence and tissue specificity of SARS-CoV-2 strains belonging to different variants of concern. The greatest virulence was possessed by the Wuhan-like Dubrovka strain, which was manifested by the development of subtotal pneumonia and maximum weight gain delay by 14.6% on average. Hamsters infected with Podolsk (Delta), Otradnoe and FEB2 strains (Omicron BA.1 and BA.5.2) lost significantly less weight,  $2-3\%$  ( $p > 0.05$ ). Greater weight loss and severe pneumonia in hamsters infected with Wuhan-like virus was associated with increased virus content in organs and viral damage to the brain. The neurovirulence of Wuhan-like virus was manifested by significantly higher viral RNA content in the brain and isolation of infectious virus from brain homogenates. A number of studies [26, 27] revealed different tropism of SARS-CoV-2 variants to brain cells and lower neurovirulence of the Omicron variant compared to Wuhan-like virus and Alpha and Delta variants, which were dominant earlier [26, 27]. Comparison of the literature data with our own data on the increased tropism of Wuhan-like virus to brain tissues suggests that it was the lesion of the central nervous system that could negatively affect the weight and general condition of the animals [28].

The results of histological examination of the lungs confirmed the data on the different virulence of the virus strains used to infect hamsters. Wuhan-like virus caused the most severe lesions in the lungs with extensive foci of bronchointerstitial pneumonia (cumulative severity score of 50) than Delta- and Omicron-like viruses (cumulative severity score of 21 to 39);  $p \leq$ 0.05. The results obtained, indicating lower virulence for hamsters of Omicron-like strains compared to the ancestral Wuhan virus, are consistent with the lower pathogenicity of the Omicron variant for humans [29], as confirmed by the lower reproductive activity of the virus in human Calu-3 lung cell culture [30]. On the other hand, early conclusions about the lower virulence of Omicron-like strains may have overestimated their attenuation for humans, since they did not separate the real decrease in virulence from the effect of prior immunity, since vaccinated and re-infected individuals naturally carry the disease more easily.

The severity of pathological changes in the lungs during infection with different strains of Omicron and Delta variants also differed significantly: the mean value of the cumulative severity score was  $21 \pm 7$  for BA.1.1,  $39 \pm 6$  for BA.5.2, and  $30 \pm 5$  for Delta. The observed higher virulence of BA.5.2 compared to Delta  $(p < 0.05)$  does not agree with the data presented in the article by S. Mohandas et al. [31], who found greater virulence of the Delta-like strain compared to the Omicron variant BA.5.2 sublineage. In this connection, it is important to note that the virulence of different virus strains may be determined not only by their belonging to a particular genetic variant, but also by strain-specific differences and the number of passages the virus isolate underwent in cell culture. It is known that virus isolation and its passages in cell culture are accompanied by the accumulation of mutations that promote virus adaptation to a new host, while virulence decreases for model laboratory animals [32]. Thus, the greater virulence of strain FEB2 (BA.5.2) can be explained by the fact that in our study this strain had undergone 4 passages in Vero cell culture before infection of hamsters, whereas the Podolsk (Delta) strain underwent 16 passages and the Otradnoe (BA.1.1) strain underwent 8 passages.

It is noteworthy that a significant content of viral RNA (up to 6.1 log10 RNA copies/mL) was detected in the heart of animals infected with different strains of SARS-CoV-2. Heart damage by SARS-CoV-2 virus in hamsters has been observed in a number of studies [33, 34]. This observation is also interesting in the context of the high probability of myocarditis in humans after COVID-19. Since ACE2 receptor expression is upregulated in human myocytes [35], the probability of SARS-CoV-2 virus infection of cardiac tissues and the risk of myocarditis development are increased [36, 37].

Among small laboratory animals, COVID-19 modeling is possible in various mouse lines, with the K18-hACE2 transgenic mice being the most susceptible to SARS-CoV-2 [5]. However, at the moment this line of mice is difficult to access, and effective reproduction of the virus in organs other than lungs makes it difficult to use this animal model for modeling viral pneumonia, because these animals have a high percentage of mortality due to causes unrelated to pneumonia. Thus, the main cause of death in K18-hACE2 mice is central nervous system damage and development of viral encephalitis and other neurological diseases due to high expression of ACE2 receptor in brain cells [18, 38, 39]. The disease in K18-hACE2 mice is more severe and has differences in the character of clinical manifestations compared to those in humans.

In view of the above, the hamster model for coronavirus pneumonia is one of the most adequate, accessible and informative among small laboratory animals. Hamsters, when infected with SARS-CoV-2, show clinical signs of respiratory disease and develop mild to moderate pneumonia [18, 40]. Furthermore, they have the ability to spread the virus with infection of contact naive animals [3, 39]. The hamster-based animal model has been widely used in preclinical trials of antiviral drugs and vaccines because it reproduces the development of viral pneumonia without animal death [13, 18, 41, 42]. This study showed that the modeling of

COVID-19 caused by new virus variants (Delta, BA.1.1 and BA.5.2) in hamsters remains relevant. These virus variants retained the ability to cause pneumonia with extensive lesions in hamsters. While weight dynamics as an indicator of virulence has become less informative, such indicators as viral load (virus infectivity and viral RNA content in organs) and severity of inflammatory changes in the lungs have retained their informative value in assessing the severity of the disease. Scoring of the severity of pathomorphologic changes in the lungs is of particular value in comparing the severity of pneumonia, because it reduces subjectivity in the evaluation of the results of histologic examination and gives a semi-quantitative assessment of the pathologic

process.

## **Conclusion**

The results of this study showed that infection in Syrian golden hamsters infected with SARS-CoV-2 strains belonging to different evolutionary lineages proceeds differently. The Wuhan-like virus was found to be more virulent and neurotropic than the Delta and Omicron variants, which became widespread later. Modeling on hamsters of COVID-19 caused by sublineages of the Omicron variant remains relevant, despite insignificant weight loss of animals, in contrast to infection with Wuhan-like virus. Histologic examination and such indicators as viral load in the lungs, nasal passages, brain, heart and a number of other organs continue to play a decisive role in assessing the pathogenicity of Omicron-like strains for hamsters.

#### СПИСОК ИСТОЧНИКОВ | REFERENCES

- 1. Fan C., Wu Y., Rui X., et al. Animal models for COVID-19: advances, gaps and perspectives. *Signal Transduct. Target. Ther*. 2022;7(1):220.
- DOI: https://doi.org/10.1038/s41392-022-01087-8 2. Roberts A., Vogel L., Guarner J., et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. *J. Virol*. 2005;79(1):503–11.
- DOI: https://doi.org/10.1128/jvi.79.1.503-511.2005
- 3. Chan J.F., Zhang A.J., Yuan S., et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: Implications for disease pathogenesis and transmissibility. *Clin. Infect. Dis*. 2020;71(9):2428–46. DOI: https://doi.org/10.1093/cid/ciaa325
- 4. Qi F., Qin C. Characteristics of animal models for COVID-19. *Animal Model. Exp. Med*. 2022;5(5):401–9. DOI: https://doi.org/10.1002/ame2.12278
- 5. Leneva I.A., Smirnova D.I., Kartashova N.P., et al. Comparative study of Wuhan-like and omicron-like variants of SARS-CoV-2 in experimental animal models. *Vopr. Virusol*. 2022;67(5):439– 49. DOI: https://doi.org/10.36233/0507-4088-135
- 6. Kirk N.M., Liang Y., Ly H. Pathogenesis and virulence of coronavirus disease: Comparative pathology of animal models for COVID-19. *Virulence*. 2024;15(1):2316438. DOI: https://doi.org/10.1080/21505594.2024.2316438
- 7. Muñoz-Fontela C., Dowling W.E., Funnell S.G.P., et al. Animal models for COVID-19. *Nature*. 2020;586(7830):509–15. DOI: https://doi.org/10.1038/s41586-020-2787-6
- 8. Fenollar F., Mediannikov O., Maurin M., et al. Mink, SARS-CoV-2, and the human-animal interface. *Front. Microbiol*. 2021;12:663815.
- DOI: https://doi.org/10.3389/fmicb.2021.663815
- 9. Kutter J.S., de Meulder D., Bestebroer T.M., et al. SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets over more than one meter distance. *Nat. Commun*. 2021;12(1):1653. DOI: https://doi.org/10.1038/s41467-021-21918-6
- 10. Ciurkiewicz M., Armando F., Schreiner T., et al. Ferrets are valuable models for SARS-CoV-2 research. *Vet. Pathol*. 2022;59(4):661–72.
- DOI: https://doi.org/10.1177/03009858211071012 11. Martins M., Nooruzzaman M., Cunningham J.L., et al. The SARS-CoV-2 spike is a virulence determinant and plays a major role on the attenuated phenotype of Omicron virus in a feline model of infection. *J. Virol*. 2024;98(3):e0190223. DOI: https://doi.org/10.1128/jvi.01902-23
- 12. Bao L., Deng W., Huang B., et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature*. 2020;583(7818):830–3. DOI: https://doi.org/10.1038/s41586-020-2312-y
- 13. Xue Y., Yang D., Vogel P., et al. Cardiopulmonary Injury in the Syrian hamster model of COVID-19. *Viruses*. 2022;14(7):1403. DOI: https://doi.org/10.3390/v14071403
- 14. Miao J., Chard L.S., Wang Z., Wang Y. Syrian hamster as an animal model for the study on infectious diseases. *Front. Immunol*. 2019;10:2329. DOI: https://doi.org/10.3389/fimmu.2019.02329
- 15. Iwatsuki-Horimoto K., Nakajima N., Ichiko Y., et al. Syrian hamster as an animal model for the study of human influenza virus infection. *J. Virol*. 2018;92(4):e01693–17. DOI: https://doi.org/10.1128/JVI.01693-17
- 16. Fan S., Gu C., Kong H., et al. Influenza viruses suitable for studies in Syrian hamsters. *Viruses*. 2022;14(8):1629. DOI: https://doi.org/10.3390/v14081629
- 17. Toth K., Lee S.R., Ying B., et al. STAT2 knockout Syrian hamsters support enhanced replication and pathogenicity of human adenovirus, revealing an important role of type I interferon response in viral control. *PLoS Pathog*. 2015;11(8):e1005084. DOI: https://doi.org/10.1371/journal.ppat.1005084
- 18. Rosenke K., Meade-White K., Letko M., et al. Defining the Syrian hamster as a highly susceptible preclinical model for SARS-

CoV-2 infection. *Emerg. Microbes Infect*. 2020;9(1):2673–84. DOI: https://doi.org/10.1080/22221751.2020.1858177

- 19. Xu J., Liu M., Niu X., et al. The cold-adapted, temperature-sensitive SARS-CoV-2 strain TS11 is attenuated in Syrian hamsters and a candidate attenuated vaccine. *Viruses*. 2022;15(1):95. DOI: https://doi.org/10.3390/v15010095
- 20. Wang Y., Yang C., Song Y., et al. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. *Proc. Natl. Acad. Sci. U.S.A*. 2021;118(29):e2102775118. DOI: https://doi.org/10.1073/pnas.2102775118
- 21. Faizuloev E.B., Gracheva A., Korchevaya E.R., et al. Single intranasal immunization with attenuated Wuhan-like SARS-CoV-2 provides highly effective cross-protection against Delta and Omicron variants of concern: 1. *J. Microbiol. Epidemiol. Immunobiol*. 2024;101(1):36–51. DOI: https://doi.org/10.21203/rs.3.rs-3279049/v1
- 22. Ramakrishnan M.A. Determination of 50% endpoint titer using a simple formula. *World J. Virol*. 2016;5(2):85–6. DOI: https://doi.org/10.5501/wjv.v5.i2.85
- 23. Gracheva A.V., Korchevaya E.R., Ammour Y.I., et al. Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light. *Arch. Virol*. 2022;167(11):2181–91. DOI: https://doi.org/10.1007/s00705-022-05530-7
- 24. Chan J.F., Yip C.C., To K.K., et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. *J. Clin. Microbiol*. 2020;58(5):e00310-20. DOI: https://doi.org/10.1128/JCM.00310-20
- 25. Gruber A.D., Osterrieder N., Bertzbach L.D., et al. Standardization of reporting criteria for lung pathology in SARS-CoV-2 infected hamsters: what matters? *Am. J. Respir. Cell Mol. Biol*. 2020;63(6):856–9.

DOI: https://doi.org/10.1165/rcmb.2020-0280LE

- 26. Bauer L., van Riel D. Do SARS-CoV-2 variants differ in their neuropathogenicity? *mBio*. 2023;14(1):e0292022. DOI: https://doi.org/10.1128/mbio.02920-22
- 27. Bauer L., Rissmann M., Benavides F.F.W., et al. In vitro and in vivo differences in neurovirulence between D614G, Delta and Omicron BA.1 SARS-CoV-2 variants. *Acta Neuropathol. Commun*. 2022;10(1):124.
- DOI: https://doi.org/10.1186/s40478-022-01426-4 28. Bauer L., Laksono B.M., de Vrij F.M.S., et al. The neuroinva-
- siveness, neurotropism, and neurovirulence of SARS-CoV-2. *Trends Neurosci*. 2022;45(5):358–68. DOI: https://doi.org/10.1016/j.tins.2022.02.006
- 29. Trunfio M., Portesani F., Vicinanza S., et al. Real-life evidence of lower lung virulence in COVID-19 inpatients infected with SARS-CoV-2 Omicron variant compared to wild-type and Delta SARS-CoV-2 pneumonia. *Lung*. 2022;200(5):573–7. DOI: https://doi.org/10.1007/s00408-022-00566-7
- 30. Purwono P.B., Vacharathit V., Manopwisedjaroen S., et al. Infection kinetics, syncytia formation, and inflammatory biomarkers as predictive indicators for the pathogenicity of SARS-CoV-2 Variants of Concern in Calu-3 cells. *PLoS One*. 2024;19(4):e0301330.

DOI: https://doi.org/10.1371/journal.pone.0301330

- 31. Mohandas S., Shete A., Kumar A., et al. Comparative pathogenicity of BA.2.12, BA.5.2 and XBB.1 with the Delta variant in Syrian hamsters. *Front. Microbiol*. 2023;14:1183763. DOI: https://doi.org/10.3389/fmicb.2023.1183763
- 32. Li X.F., Cui Z., Fan H., et al. A highly immunogenic live-attenuated vaccine candidate prevents SARS-CoV-2 infection and transmission in hamsters. *Innovation (Camb).* 2022;3(2):100221. DOI: https://doi.org/10.1016/j.xinn.2022.100221
- 33. Daems M., Liesenborghs L., Boudewijns R., et al. SARS-CoV-2 infection causes prolonged cardiomyocyte swelling and inhibition of HIF1α translocation in an animal model COVID-19.

*Front. Cardiovasc. Med*. 2022;9:964512. DOI: https://doi.org/10.3389/fcvm.2022.964512

ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ

- 34. Jones E.A.V. Mechanism of COVID-19-induced cardiac damage from patient, *in vitro* and animal studies. *Curr. Heart Fail Rep*. 2023;20(5):451–60. DOI: https://doi.org/10.1007/s11897-023-00618-w
- 35. Liu H., Gai S., Wang X., et al. Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart. *Cardiovasc. Res*. 2020;116(10):1733–41.
	- DOI: https://doi.org/10.1093/cvr/cvaa191
- 36. Ishisaka Y., Watanabe A., Aikawa T., et al. Overview of SARS-CoV-2 infection and vaccine associated myocarditis compared to non-COVID-19-associated myocarditis: a systematic review and meta-analysis. *Int. J. Cardiol*. 2024;395:131401. DOI: https://doi.org/10.1016/j.ijcard.2023.131401
- 37. Thaker R., Faraci J., Derti S., Schiavone J.F. Myocarditis in SARS-CoV-2: A meta-analysis. *Cureus*. 2023;15(10):e48059. DOI: https://doi.org/10.7759/cureus.48059
- 38. Jiang R.D., Liu M.Q., Chen Y., et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-con-

verting enzyme 2. *Cell*. 2020;182(1):50-58.e8. DOI: https://doi.org/10.1016/j.cell.2020.05.027

- 39. Sia S.F., Yan L.M., Chin A.W.H., et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. *Nature*. 2020;583(7818):834–8. DOI: https://doi.org/10.1038/s41586-020-2342-5
- 40. Imai M., Iwatsuki-Horimoto K., Hatta M., et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. *Proc. Natl. Acad. Sci. U.S.A*. 2020;117(28):16587–95.

DOI: https://doi.org/10.1073/pnas.2009799117

- 41. Yuan S., Ye Z.W., Liang R., et al. Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. *Science*. 2022;377(6604):428–33. DOI: https://doi.org/10.1126/science.abn8939
- 42. Mohandas S., Yadav P.D., Sapkal G., et al. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern. *EBio-Medicine*. 2022;79:103997. DOI: https://doi.org/10.1016/j.ebiom.2022.103997

[ORIGINAL RESEARCHES](#page-0-0)

#### **Information about the authors**

*Anastasiia V. Gracheva* — researcher, Applied virology laboratory, I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia, anastasiia.gracheva.95@mail.ru,

https://orcid.org/0000-0001-8428-4482

*Andrey O. Drokov* — student, intern, Applied virology laboratory, I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia, https://orcid.org/0009-0006-3300-8078

*Daria I. Smirnova* — junior researcher, Applied virology laboratory, I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia, https://orcid.org/0000-0001-7325-0834

*Darya M. Khokhlova* — junior researcher, Applied virology laboratory, I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia, https://orcid.org/0009-0003-5745-7589

*Ekaterina R. Korchevaya* — junior researcher, Applied virology laboratory, I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia, https://orcid.org/0000-0002-6417-3301

*Andrey A. Pankratov* — Cand. Sci. (Biol.), Head, Department of experimental pharmacology and toxicology, P.A. Hertsen Moscow Oncology Research Institute, National Medical Research Radiological Center, Moscow, Russia, https://orcid.org/0000-0001-7291-9743

*Galina V. Trunova* — Cand. Sci. (Biol.), senior researcher, Department of experimental pharmacology and toxicology, P.A. Hertsen Moscow Oncology Research Institute, National Medical Research Radiological Center, Moscow, Russia,

https://orcid.org/0000-0003-2917-4496

*Varvara A. Khokhlova* — junior researcher, Department of experimental pharmacology and toxicology, P.A. Hertsen Moscow Oncology Research Institute, National Medical Research Radiological Center, Moscow, Russia, https://orcid.org/0000-0002-0339-2068

*Maria S. Vorontsova* — Cand. Sci. (Biol.), junior researcher, Department of experimental pharmacology and toxicology, P.A. Hertsen Moscow Oncology Research Institute, National Medical Research Radiological Center, Moscow, Russia,

https://orcid.org/0000-0002-9320-1746

*Irina A. Leneva —* D. Sci. (Biol.), Head, Experimental virology laboratory, I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia, https://orcid.org/0000-0002-7755-2714

*Oksana A. Svitich* — D. Sci. (Med.), Prof., Corresponding Member of RAS, Director, I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; Prof., Department of microbiology, virology and immunology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia,

https://orcid.org/0000-0003-1757-8389

*Vitaly V. Zverev* — D. Sci. (Biol.), Prof., Academician of RAS, scientific director, I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; Head, Department of microbiology, virology and immunology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia,

https://orcid.org/0000-0001-5808-2246

*Evgeny B. Faizuloev* — Cand. Sci. (Biol.), Head, Applied virology laboratory, I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; senior lecturer, Department of virology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia, https://orcid.org/0000-0001-7385-5083

**Author contributions:** *Gracheva А.V.* — research design, experiments, writing and editing the manuscript; *Drokov А.О., Smirnova D.I., Khokhlova D.М., Korchevaya Е.R.* — experiments, data collection, statistical analysis; *Pankratov А.А., Trunova G.V., Khokhlova V.А., Vorontsova М.С.* — histology; *Leneva I.А., Svitich О.А., Zverev V.V.* — methodology, revision of the manuscript. *Faizuloev Е.B.* — research conception, methodology, writing and editing the manuscript. Аll authors confirm that they meet the International Committee of Medical Journal Editors criteria for authorship, made a substantial contribution to the conception of the work, acquisition, analysis, interpretation of data for the work, drafting and revising the work, final approval of the version to be published.

> The article was submitted 01.05.2024; accepted for publication 02.07.2024; published 29.08.2024

#### *Информация об авторах*

*Грачева Анастасия Вячеславовна —* н.с лаб. прикладной вирусологии НИИВС им. И.И. Мечникова, Москва, Россия, anastasiia. gracheva.95@mail.ru,

https://orcid.org/0000-0001-8428-4482

*Дроков Андрей Олегович* — стажёр лаб. прикладной вирусологии НИИВС им. И.И. Мечникова, Москва, Россия, https://orcid.org/0009-0006-3300-8078

*Смирнова Дарья Ильинична —* м.н.с. лаб. прикладной вирусологии НИИВС им. И.И. Мечникова, Москва, Россия, https://orcid.org/0000-0001-7325-0834

*Хохлова Дарья Михайловна —* м.н.с. лаб. прикладной вирусологии НИИВС им. И.И. Мечникова, Москва, Россия, https://orcid.org/0009-0003-5745-7589

*Корчевая Екатерина Романовна —* м.н.с. лаб. прикладной вирусологии НИИВС им. И.И. Мечникова, Москва, Россия, https://orcid.org/0000-0002-6417-3301

*Панкратов Андрей Александрович —* к.б.н., зав. отделением экспериментальной фармакологии и токсикологии МНИОИ им. П.А. Герцена — филиала НМИЦ радиологии, Москва, Россия, https://orcid.org/0000-0001-7291-9743

*Трунова Галина Владимировна —* к.б.н., с.н.с. отделения экспериментальной фармакологии и токсикологии МНИОИ им. П.А. Герцена — филиала НМИЦ радиологии, Москва, Россия, https://orcid.org/0000-0003-2917-4496

*Хохлова Варвара Андреевна —* м.н.с. отделения экспериментальной фармакологии и токсикологии МНИОИ им. П.А. Герцена — филиала НМИЦ радиологии, Москва, Россия, https://orcid.org/0000-0002-0339-2068

*Воронцова Мария Сергеевна —* к.б.н., м.н.с. отделения экспериментальной фармакологии и токсикологии МНИОИ им. П.А. Герцена — филиала НМИЦ радиологии, Москва, Россия, https://orcid.org/0000-0002-9320-1746

*Ленева Ирина Анатольевна —* д.б.н., зав. лаб. экспериментальной вирусологии НИИВС им. И.И. Мечникова, Москва, Россия, https://orcid.org/0000-0002-7755-2714

*Свитич Оксана Анатольевна —* д.м.н., профессор, член-корр. РАН, директор НИИВС им. И.И. Мечникова, Москва, Россия; профессор каф. микробиологии, вирусологии и иммунологии Медико-профилактического факультета Первого МГМУ им. И.М. Сеченова (Сеченовский Университет), Москва, Россия, https://orcid.org/0000-0003-1757-8389

*Зверев Виталий Васильевич —* д.б.н., профессор, академик РАН, научный руководитель НИИВС им. И.И. Мечникова, Москва, Россия; зав. каф. микробиологии, вирусологии и иммунологии Медико-профилактического факультет Первого МГМУ им. И.М. Сеченова (Сеченовский Университет), Москва, Россия, https://orcid.org/0000-0001-5808-2246

*Файзулоев Евгений Бахтиерович* — к.б.н., зав. лаб. прикладной вирусологии НИИВС им. И.И. Мечникова, Москва, Россия; старший преподаватель кафедры вирусологии РМАНПО, Москва, Россия, https://orcid.org/0000-0001-7385-5083

**Вклад авторов:** *Грачева А.В.* — дизайн исследования, экспериментальная часть, написание статьи; *Дроков А.О., Смирнова Д.И., Хохлова Д.М., Корчевая Е.Р.* — экспериментальная часть, сбор и анализ данных, визуализация; *Панкратов А.А., Трунова Г.В., Хохлова В.А., Воронцова М.С.* — гистологическое исследование лёгких; *Ленева И.А., Свитич О.А., Зверев В.В.* методология, редактирование статьи; *Файзулоев Е.Б.* — концепция исследования, методология, написание и редактирование статьи. Все авторы подтверждают соответствие своего авторства критериям ICMJE, внесли существенный вклад в проведение поисково-аналитической работы и подготовку статьи, прочли и одобрили финальную версию до публикации.

> Статья поступила в редакцию 01.05.2024; принята к публикации 02.07.2024; опубликована 29.08.2024